## Journal of Pharmacology and Experimental Therapeutics

## Supplemental data

## Dual-Modified Liposome for Targeted and Enhanced Gene Delivery into Mice Brain

Bruna dos Santos Rodrigues, Sushant Lakkadwala, Takahisa Kanekiyo and Jagdish Singh

**Supplemental Table 1:** Participle size and encapsulation efficiency of kFGFTf-liposomes (380 nM phospholipid) containing different amount of pDNA-chitosan complexes

Characterization of	kFGFTf-liposomes				
liposomes	380 nM phospholipid + 25 μg pDNA	380 nM phospholipid + 500 μg pDNA			
F · · · ·	complexed to chitosan (N/P=5)	complexed to chitosan (N/P=5)			
Particle size	153.1±3.72	154.3±1.35			
Encapsulation Efficiency	91.3±5.54%	89.5±0,91%			

a	Mel-lip	MelTf-lip	kFGF-lip	kFGFTf-lip	PasR8-lip	PasR8Tf-lip
Amiloride						
Chlorpromazine						
Colchicine	****					
Sodium Azide						
Control						
Amiloride <b>q</b>				1977 - 1989 - 1997		
Chlorpromazine	anna Tagh <u>à</u> s	X.		All and a second		
Colchicine	1		A alter	at a day	12. A.	A C
Sodium Azide		1.00				
Control			100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 			
Amiloride C	1- True		1.	1		
Chlorpromazine	No. Ca				Sug	
Colchicine			1.1			
Sodium Azide			1900 - 1900 1900 -			
Control	K.			A. Co		

**Supplemental Figure 1.** Fluorescence microscopy images indicating the effect on uptake of Mel-lip, MelTf-lip, kFGF-lip, kFGFTf-lip, PasR8-lip and PasR8Tf-liposomes after 4 h of incubation in bEnd.3 (a), primary astrocytes (b) and primary neuronal cells (c) pretreated with endocytosis inhibitors (amiloride, chlorpromazine, colchicine and sodium azide) (Scale bar depicts  $100 \mu$ m).



**Supplemental Figure 2.**  $\beta$ -galactosidase activity induced in bEnd.3 (a), primary astrocytes (b) and primary neuronal cells (c) after 48 h of treatment with Mel-lip, MelTf-lip, kFGF-lip, kFGFTf-lip, PasR8-lip and PasR8Tf -liposomes containing chitosan-p $\beta$ gal complexes as determined by  $\beta$ gal assay kit. Data are expressed as mean  $\pm$  SD (n=4). Statistically significant (p<0.05) differences are shown as (\*) with control, (#) with Lipofectamine 3000 and (†) with Mel-lip, kFGF-lip and PasR8-liposomes.



**Supplemental Figure 3.** *In vivo* biodistribution of Mel-lip, MelTf-lip, kFGF-, kFGFTf-, PasR8and PasR8Tf-liposomes in liver, kidneys, heart, lungs, spleen and blood of CB57BL/6J mice after 24 h of liposomal administration. Data are expressed as mean  $\pm$  SE (n=6). Statistically significant (p<0.05) differences are shown as (\*).



**Supplemental Figure 4.** Near-Infrared (NIR) imaging of relative fluorescence intensity in liver, kidneys, heart, lungs and spleen from C57BL/6J mice 24 h after administration of Mel-lip, MelTf-lip, kFGF-lip, kFGFTf-lip, PasR8-lip and PasR8Tf-liposomes.